Merck Gets PTAB To Nix Johns Hopkins Cancer Drug Patent

By Theresa Schliep · June 10, 2025, 3:18 PM EDT

Merck & Co. Inc. subsidiary Merck Sharp & Dohme LLC has notched a win at the Patent Trial and Appeal Board in its disagreement with Johns Hopkins University over a cancer research...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Final Written Decision

Case Information

Case Title

Merck Sharp & Dohme LLC v. The Johns Hopkins University

Case Number

Court

Maryland

Nature of Suit

Patent

Date Filed

November 29, 2022

Recent Articles By Theresa

June 06, 2025
Fed. Circ. Weighs Purview Over Acorda's $17M Arbitral Award
June 05, 2025
Sens. Float Automatic Biosimilar Interchangeable Label
June 02, 2025
Defamation Litigation Roundup: Cheetos, NASCAR, OpenAI
May 19, 2025
Bluebird Beats Patent Case Over Blood Disease Therapies
May 08, 2025
Fed. Circ. Weighs If Expert's Testimony Justifies Spine IP Loss
May 05, 2025
Liquidia Fends Off Indication Challenge In UTC Tyvaso Fight
April 22, 2025
J&J Ends Trade Secrets Suit Against Now Deceased Ex-Exec
April 03, 2025
Senate Panel Advances Bills Tackling Drug Patents, Pricing
April 01, 2025
Two More Pharmacies Hit With Eli Lilly Weight Loss Drug Suits
March 14, 2025
Fed. Circ. Affirms No Block On Amgen's Eye Med Biosimilar